9FZI
A new crystal structure of the hPXR-LBD in fusion with an SRC1 co-activator peptide and in complex with SR12813 (P212121 form)
Summary for 9FZI
| Entry DOI | 10.2210/pdb9fzi/pdb |
| Descriptor | Nuclear receptor subfamily 1 group I member 2,Nuclear receptor coactivator 1, [2-(3,5-DI-TERT-BUTYL-4-HYDROXY-PHENYL)-1-(DIETHOXY-PHOSPHORYL)-VINYL]-PHOSPHONIC ACID DIETHLYL ESTER (3 entities in total) |
| Functional Keywords | nuclear receptor, ligand binding domain, pxr, transcription |
| Biological source | Homo sapiens (human) More |
| Total number of polymer chains | 2 |
| Total formula weight | 79968.02 |
| Authors | Carivenc, C.,Blanc, P.,Bourguet, W.,Delfosse, V. (deposition date: 2024-07-05, release date: 2025-02-19, Last modification date: 2025-03-12) |
| Primary citation | Carivenc, C.,Laconde, G.,Blanc, P.,Amblard, M.,Bourguet, W.,Delfosse, V. A two-in-one expression construct for biophysical and structural studies of the human pregnane X receptor ligand-binding domain, a pharmaceutical and environmental target. Acta Crystallogr.,Sect.F, 81:85-94, 2025 Cited by PubMed Abstract: The ligand-binding domain (LBD) of the human nuclear receptor pregnane X receptor (PXR) is known to crystallize in two different crystal forms, P222 or P422, depending on the construct and the strategy used for protein production, as well as the presence or absence of the coactivator-derived peptide SRC-1. In order to facilitate biophysical and structural studies, a versatile construct was designed that allows access to both forms. This was achieved by introducing a thrombin cleavage site between the PXR and the SRC-1 peptide fused to its C-terminus. Here, we describe the expression, purification and crystallization processes of this novel construct and report two new structures of PXR that were obtained thanks to this strategy. PubMed: 39923198DOI: 10.1107/S2053230X2500069X PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (2.7 Å) |
Structure validation
Download full validation report
